AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30871958 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping (PT)
Number of subjects: 30
Study 30139332 — intervention group
Group type: EXPERIMENTAL
Intervention: Email guided positive psychology intervention (PP)
Number of subjects: 275
Study 30139332 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 275
Study 27341028 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline bitartrate (2.0-2.5g)
Number of subjects: 94
Study 27341028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 24252064 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide prevention programme (8 sessions over 4 weeks, 2 sessions per week)
Number of subjects: 45
Study 24252064 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments in the hospital (Control group)
Number of subjects: 45
Study 22300491 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 60
Study 22300491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 60
Study 20369558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of improved sex therapy and oral sildenafil for 3 months
Number of subjects: 3130
Study 20369558 — intervention group
Group type: COMPARATOR
Intervention: Oral sildenafil alone for 3 months
Number of subjects: 3130
Study 18759568 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 13
Study 15983302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 107
Study 15983302 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 107
Study 15983302 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 107
Study 15983302 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 107
Study 15983302 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII and MDI
Number of subjects: 107
Study 12456446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (15 mg/kg/day in 3 divided doses)
Number of subjects: 18
Study 12456446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10546710 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy with two 1-g doses of intramuscular ceftriaxone at 24-hour intervals followed by oral cephalexin
Number of subjects: 92
Study 10546710 — intervention group
Group type: COMPARATOR
Intervention: Inpatient therapy with two 1-g doses of intramuscular ceftriaxone at 24-hour intervals followed by oral cephalexin
Number of subjects: 92
Study 10546710 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy
Number of subjects: 92
Study 10546710 — intervention group
Group type: COMPARATOR
Intervention: Inpatient therapy
Number of subjects: 92
Study 7573232 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of thyrotropin‐releasing hormone
Number of subjects: 26
Study 7573232 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of thyrotropin‐releasing hormone
Number of subjects: 26
Study 7573232 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 2347114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ciclopiroxolamine solution applied once daily for 1, 2, or 3 days
Number of subjects: 6
Study 2347114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ciclopiroxolamine solution
Number of subjects: 6
Study 2347114 — intervention group
Group type: COMPARATOR
Intervention: KOH direct microscopy
Number of subjects: 6
Study 373072 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg)
Number of subjects: 36
Study 373072 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 36
Study 373072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 36
Study 6670732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg)
Number of subjects: 150
Study 6670732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg) and Atropine (0.01 mg/kg b.w.)
Number of subjects: 150
Study 6670732 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar (Fentanyl (0.1 mg) and Droperidol (5 mg))
Number of subjects: 150
Study 6670732 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar (Fentanyl (0.1 mg) and Droperidol (5 mg)) plus Atropine (0.01 mg/kg b.w.)
Number of subjects: 150
Study 6670732 — intervention group
Group type: COMPARATOR
Intervention: Control group (Atropine only)
Number of subjects: 150
Study 6670732 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine-free groups with Innovar
Number of subjects: 150
Study 30883055 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4614
Study 30883055 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist
Number of subjects: 4614
Study 30883055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4614
Study 30883055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4614
Study 29597112 — intervention group
Group type: EXPERIMENTAL
Intervention: Long version of manual teaching imagery rescripting
Number of subjects: 127
Study 29597112 — intervention group
Group type: COMPARATOR
Intervention: Brief version of manual teaching imagery rescripting
Number of subjects: 127
Study 29597112 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 127
Study 27510595 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI 320 μg/day
Number of subjects: 0
Study 27510595 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI 640 μg/day
Number of subjects: 0
Study 27510595 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI 640 μg/day
Number of subjects: 0
Study 27510595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24702835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg per day) plus folic acid
Number of subjects: 1078
Study 24702835 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus folic acid
Number of subjects: 1078
Study 24702835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg per day) plus folic acid in original stratum
Number of subjects: 1078
Study 24702835 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus folic acid in original stratum
Number of subjects: 1078
Study 24702835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg per day) plus folic acid in expanded stratum
Number of subjects: 1078
Study 24702835 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus folic acid in expanded stratum
Number of subjects: 1078
Study 22261747 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring (BIS-open arm)
Number of subjects: 144
Study 22261747 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring of sedation only (BIS-blinded arm)
Number of subjects: 144
Study 20951285 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 50
Study 20951285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine
Number of subjects: 50
Study 16978666 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidimensional rule-based condition
Number of subjects: 0
Study 16978666 — intervention group
Group type: EXPERIMENTAL
Intervention: Other two rule-based conditions
Number of subjects: 0
Study 16978666 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention demands
Number of subjects: 0
Study 16978666 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory demands
Number of subjects: 0
Study 15848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction (2 mg/kg) on PTD 0 and 14
Number of subjects: 25
Study 15848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin induction (1.5 mg/kg) on PTD 0 and 2 followed by daclizumab on POD 14
Number of subjects: 25
Study 12222700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day) therapy adjunctive to thrombolytic therapy
Number of subjects: 77
Study 9788392 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomotic ring
Number of subjects: 119
Study 9788392 — intervention group
Group type: COMPARATOR
Intervention: Handsewn anastomosis
Number of subjects: 119
Study 9788392 — intervention group
Group type: COMPARATOR
Intervention: Elective biofragmentable anastomotic ring
Number of subjects: 119
Study 7714788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (0, 37.5, 75, 150 or 300 mg/70 kg)
Number of subjects: 10
Study 2667749 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (M) at 4 mg/kg combined with dexamethasone (D) at 40 mg
Number of subjects: 209
Study 2667749 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (M) at 1, 2, and 4 mg/kg total dose
Number of subjects: 209
Study 840119 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation starting on the 7th day after myocardial infarction
Number of subjects: 201
Study 840119 — intervention group
Group type: COMPARATOR
Intervention: Control group mobilized after 3 weeks of bed rest
Number of subjects: 201
Study 840119 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with 3 weeks of bed rest for patients not suitable for early mobilisation
Number of subjects: 201
Study 30521653 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrostomy height of 4 mm (Group A)
Number of subjects: 24
Study 30521653 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrostomy height of 8 mm (Group B)
Number of subjects: 24
Study 28054261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 91
Study 28054261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 26458774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone monotherapy
Number of subjects: 0
Study 23591780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin (RG1678)
Number of subjects: 0
Study 21241447 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Number of subjects: 109
Study 21241447 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study 19123484 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Feedback (VF)
Number of subjects: 36
Study 19123484 — intervention group
Group type: COMPARATOR
Intervention: No Video Feedback (Control)
Number of subjects: 36
Study 17225002 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 48
Study 15115831 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-nucleoside group (zidovudine-lamivudine-abacavir)
Number of subjects: 1147
Study 15115831 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz groups (zidovudine-lamivudine plus efavirenz and zidovudine-lamivudine-abacavir plus efavirenz)
Number of subjects: 1147
Study 10828749 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive H. pylori testing
Number of subjects: 0
Study 10828749 — intervention group
Group type: COMPARATOR
Intervention: Eradication of H. pylori infection
Number of subjects: 0
Study 8636172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented unipolar prosthesis (Thompson)
Number of subjects: 0
Study 8636172 — intervention group
Group type: COMPARATOR
Intervention: Cemented bipolar prosthesis (Monk)
Number of subjects: 0
Study 1568631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g i.v. cefotaxime
Number of subjects: 119
Study 1568631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g amoxicillin plus clavulanic acid
Number of subjects: 119
Study 4068610 — intervention group
Group type: COMPARATOR
Intervention: Antacid (group A)
Number of subjects: 24
Study 4068610 — intervention group
Group type: COMPARATOR
Intervention: H2 blocker (group B)
Number of subjects: 24
Study 4068610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (group A and B)
Number of subjects: 24
Study 31722697 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized arch support orthosis (CASO)
Number of subjects: 12
Study 31722697 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic heel lift (HL)
Number of subjects: 12
Study 31722697 — intervention group
Group type: COMPARATOR
Intervention: Without orthotics
Number of subjects: 12
Study 29417495 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Care Intervention (CCI)
Number of subjects: 349
Study 29417495 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 349
Study 24387078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily combined with sildenafil 50 mg as needed
Number of subjects: 180
Study 24387078 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg once daily
Number of subjects: 180
Study 23905949 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral percutaneous pedicle screw fixation
Number of subjects: 53
Study 23905949 — intervention group
Group type: COMPARATOR
Intervention: Bilateral percutaneous pedicle screw fixation
Number of subjects: 53
Study 21964220 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast massage (two 30-minute sessions within 10 days postpartum)
Number of subjects: 60
Study 21964220 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study 18248281 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARITE Artificial Disc
Number of subjects: 0
Study 18248281 — intervention group
Group type: COMPARATOR
Intervention: BAK devices
Number of subjects: 0
Study 16569261 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (C group, 20 patients)
Number of subjects: 74
Study 16569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime with amikacin (C-A group, 19 patients)
Number of subjects: 74
Study 16569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime with levofloxacin (C-L group, 20 patients)
Number of subjects: 74
Study 16569261 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (C group)
Number of subjects: 74
Study 16569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime with amikacin (C-A group)
Number of subjects: 74
Study 16569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime with levofloxacin (C-L group)
Number of subjects: 74
Study 15041274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidpoint ENOX
Number of subjects: 166
Study 11025707 — intervention group
Group type: EXPERIMENTAL
Intervention: CaverMap group (nerve sparing assisted by the CaverMap Surgical Aid)
Number of subjects: 61
Study 11025707 — intervention group
Group type: COMPARATOR
Intervention: Conventional nerve sparing group
Number of subjects: 61
Study 11025707 — intervention group
Group type: EXPERIMENTAL
Intervention: CaverMap group
Number of subjects: 61
Study 11025707 — intervention group
Group type: EXPERIMENTAL
Intervention: CaverMap group (bilateral response)
Number of subjects: 61
Study 11025707 — intervention group
Group type: EXPERIMENTAL
Intervention: CaverMap group (unilateral response)
Number of subjects: 61
Study 11025707 — intervention group
Group type: EXPERIMENTAL
Intervention: CaverMap group (no response)
Number of subjects: 61
Study 8624266 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive calcitonin
Number of subjects: 36
Study 1375731 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program intervention (combining early child development and family support services with pediatric follow-up)
Number of subjects: 0
Study 1375731 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program intervention
Number of subjects: 0
Study 3919604 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms b.d.)
Number of subjects: 43
Study 3919604 — intervention group
Group type: COMPARATOR
Intervention: Disodium Cromoglycate (DSCG) (5.2 mg 5 times daily)
Number of subjects: 43
Study 3919604 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 43
Study 29961573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antagonist)
Number of subjects: 117
Study 29374714 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily)
Number of subjects: 144
Study 29374714 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily)
Number of subjects: 144
Study 29374714 — intervention group
Group type: EXPERIMENTAL
Intervention: N3 patients with metastases to two or more N3 regions
Number of subjects: 144
Study 26708475 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care management of NVP
Number of subjects: 0
Study 26708475 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management of NVP
Number of subjects: 0
Study 23949963 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 μg
Number of subjects: 246
Study 23949963 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 125 μg
Number of subjects: 246
Study 23949963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 22134669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cauterization of the inferior turbinate artery
Number of subjects: 60
Study 22134669 — intervention group
Group type: COMPARATOR
Intervention: Cauterization negative group (control)
Number of subjects: 60
Study 20180611 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0
Study 20180611 — intervention group
Group type: COMPARATOR
Intervention: No Proton Pump Inhibitors (PPIs)
Number of subjects: 0
Study 18797405 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ+training (TT), n=30, received TMZ 20 mg three times daily for 8 weeks and underwent exercise training at 60% of oxygen uptake at peak, three times a week for 8 weeks.
Number of subjects: 116
Study 18797405 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ (n=30), received TMZ 20 mg three times daily for 8 weeks without exercise training.
Number of subjects: 116
Study 18797405 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E, n=30), completed exercise training without receiving TMZ.
Number of subjects: 116
Study 18797405 — intervention group
Group type: COMPARATOR
Intervention: Control (C, n=26), neither exercised nor received TMZ.
Number of subjects: 116
Study 16170062 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1
Study 16170062 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 1
Study 12958567 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 23
Study 12958567 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 23
Study 12958567 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 11009863 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 prepayment
Number of subjects: 0
Study 11009863 — intervention group
Group type: COMPARATOR
Intervention: $20 postpayment
Number of subjects: 0
Study 11009863 — intervention group
Group type: EXPERIMENTAL
Intervention: $25 postpayment
Number of subjects: 0
Study 8430276 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal perfusion with pancreaticobiliary juice at a rate of 5 ml/min for 10 min
Number of subjects: 8
Study 8430276 — intervention group
Group type: COMPARATOR
Intervention: Saline at a rate of 5 ml/min for 10 min
Number of subjects: 8
Study 2441643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose challenge
Number of subjects: 68
Study 2441643 — intervention group
Group type: COMPARATOR
Intervention: Milk challenge
Number of subjects: 68
Study 31997509 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg Livergol capsule per day for 30 days
Number of subjects: 74
Study 31997509 — intervention group
Group type: COMPARATOR
Intervention: Starch-containing capsule as a placebo once a day for 30 days
Number of subjects: 74
Study 25895509 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 97
Study 25895509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 27819257 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Number of subjects: 0
Study 27819257 — intervention group
Group type: COMPARATOR
Intervention: Empirical antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Number of subjects: 0
Study 26088044 — intervention group
Group type: EXPERIMENTAL
Intervention: Information (child and carer received information on the health benefits of water)
Number of subjects: 334
Study 26088044 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement (information + free small bottles of still water delivered at home)
Number of subjects: 334
Study 26088044 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement + Community (child and caregiver engaged in an online community forum)
Number of subjects: 334
Study 26088044 — intervention group
Group type: EXPERIMENTAL
Intervention: Community (engagement in an online community forum)
Number of subjects: 334
Study 26088044 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study 24304990 — intervention group
Group type: COMPARATOR
Intervention: Insulin (group-A)
Number of subjects: 68
Study 24304990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (group-B)
Number of subjects: 68
Study 20708850 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan_4D (adaptive radiotherapy)
Number of subjects: 13
Study 20708850 — intervention group
Group type: COMPARATOR
Intervention: Plan_3D (conventional radiotherapy)
Number of subjects: 13
Study 19484982 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) by nasal spray
Number of subjects: 90
Study 19484982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling
Number of subjects: 90
Study 19484982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray-inhaling combined administration
Number of subjects: 90
Study 16887471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 1500 mg day(‐1)
Number of subjects: 26
Study 16887471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 1000 mg day(‐1)
Number of subjects: 26
Study 16887471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 500 mg every 8 h
Number of subjects: 26
Study 15646945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic brushing
Number of subjects: 47